HONG KONG/BEIJING – China is in talks with Pfizer Inc. to secure a license that would allow domestic drugmakers to manufacture and distribute a generic version of the US company’s COVID-19 antiviral drug Paxlovid in China, three sources said.
China’s medical products regulator – the National Medical Products Administration (NMPA) – has been leading talks with Pfizer since late last month, according to one of the knowledgeable sources.
Beijing would like to finalize the terms of the license agreement before the Lunar New Year which begins on January 22, the source said.
In an age of both misinformation and too much information, quality journalism is more important than ever.
By subscribing you can help us get the story right.